Richmond Pharmacology is pleased to confirm our attendance at the EASL Congress 2025 in Amsterdam, one of the leading global events dedicated to liver research and hepatology, hosted by the European Association for the Study of the Liver.

This year’s congress will bring together experts from across the world to share the latest developments in liver disease research, clinical innovation, and therapeutic advances.

Representing Richmond Pharmacology:

  • Dr Jörg Täubel, Chief Executive Officer

Our team looks forward to engaging with clinical leaders, researchers, and industry partners to explore opportunities in:

  • Early-phase hepatology research
  • Rare and metabolic liver disease trials
  • Regulatory strategy and scientific advice

If you are attending EASL Congress and would like to learn how Richmond Pharmacology can support your liver-focused clinical development, we welcome you to connect with us during the event.

For meeting requests or collaboration enquiries:
info@richmondpharmacology.com

Learn more about the event:

Latest news

Patient safety is not an afterthought. Explore our new infographic!

September 17, 2025
Patient safety is not an afterthought; it is the foundation of every clinical trial.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event